RECRUITING

qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research is to evaluate a new technique, quantitative digital subtraction angiography (qDSA), to measure blood flow during liver embolization procedures. Liver transarterial embolization is a way of treating liver tumors by blocking blood flow to it. The qDSA technique could help doctors ensure the blood flow to the tumor is decreased by the right amount by calculating blood flow before, during, and after the procedure. Up to 20 participants will be enrolled for 1 study visit and data collection for up to 6 months.

Official Title

qDSA Blood Flow Measurement in Patients Undergoing Transarterial Embolization (TAE) of the Liver

Quick Facts

Study Start:2025-03-13
Study Completion:2026-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06971991

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Give voluntary, written informed consent to participate in this study and willing to comply with study-related evaluation and procedure schedule
  1. * Pregnancy or breastfeeding
  2. * Patients with an acute kidney injury or stage IV or V chronic kidney disease (Cr greater than 2.4 or estimated glomerular filtration rate (eGFR) less than 30), unless anuric and on dialysis without expected return of renal function.
  3. * Patients with an iodinated contrast allergy who cannot be adequately premedicated to receive contrast as part of the embolization procedure.
  4. * Patients with a physical or psychological condition that would impair study participation.
  5. * The patient is judged unsuitable for study participation by the Investigator for any other reason

Contacts and Locations

Study Contact

Radiology Coordinators
CONTACT
608-282-8349
Radstudy@uwhealth.org

Principal Investigator

Paul Laeseke, MD, PhD
PRINCIPAL_INVESTIGATOR
UW School of Medicine and Public Health

Study Locations (Sites)

UW Hospital and Clinics
Madison, Wisconsin, 53792
United States

Collaborators and Investigators

Sponsor: University of Wisconsin, Madison

  • Paul Laeseke, MD, PhD, PRINCIPAL_INVESTIGATOR, UW School of Medicine and Public Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-03-13
Study Completion Date2026-03

Study Record Updates

Study Start Date2025-03-13
Study Completion Date2026-03

Terms related to this study

Keywords Provided by Researchers

  • Quantitative digital subtraction angiography (qDSA)

Additional Relevant MeSH Terms

  • Transarterial Embolism
  • Transarterial Chemoembolization